Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib, Obinutuzumab and Venetoclax in High Risk CLL
NCT05197192Phase 3Recruiting
- Sponsor
- German CLL Study Group
- Start
- Apr 2022
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by German CLL Study Group. Primary endpoint: Progression-free survival at 50 months. Started Apr 2022; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05197192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197192.